Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936. Abstract
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738-1748. Abstract
Hortobagyi G, Stemmer S, Burris H, et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Presented at: 2017 American Society of Clinical Oncology Annual Meeting; June 3-7, 2017; Chicago, Illinois. Abstract 1038.
di Leo A, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Presented at 2017 European Society for Medical Oncology (ESMO); September 8-12, 2017; Madrid, Spain. Abstract 2360.
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439. Abstract
Turner NC, André F, Cristofanilli M, et al. Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3. Presented at: San Antonio Breast Cancer Symposium; December 2016. San Antonio, TX. Abstract P4-22-06.
Sledge GW Jr, Masakazu T, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875-2884. Abstract
Ibrance® [package insert]. New York, NY: Pfizer Inc.; 2016.
Kisqali® [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2017.
Verzenio® [package insert]. Indianapolis, IN : Eli Lilly and Company ; 2017.
Goetz MP, Toi M, Campone M, et al. MONARCH-3 : Abemacicilb as initial therapy for advanced breast cancer. J Clin Oncol. 2017. Oct 2 :[Epub ahead of print].
Harbeck N, Cristofanilli M, Ro J, et al. A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): detailed analysis of patient-reported outcomes. Eur J Cancer. 2015;51:S270-S271.
Goel S, DeCristo M, Watt A, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471-475. Abstract
ClinicalTrials.gov. Trial of anastrozole and palbociclib in metastatic HER2-negative breast cancer. https://clinicaltrials.gov/ct2/show/NCT02942355. Accessed September 30, 2017.
ClinicalTrials.gov. Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7). https://clinicaltrials.gov/ct2/show/NCT02278120. Accessed September 28, 2017.
Finn R, Aleshin A, Slamon D. Targeting the cyclin-dependent kinases(CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18:17.
Finn RS, Crown J, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35. Abstract
Turner NC, Jiang Y, O'Leary B, et al. Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA) [abstract 512]. J Clin Oncol. 2016;34(suppl 15).
ClinicalTrials.gov. Study to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+, HER2- locally advanced or metastatic breast cancer (PARSIFAL). https://clinicaltrials.gov/ct2/show/NCT02491983. Accessed September 28, 2017.
Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor–positive breast cancer. Cancer Res. 2016;76:2301-2313. Abstract
Ma CX, Gao F, Luo J, et al. NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017;23:4055-4065. Abstract
Arnedos M, Cheaib B, Bayar M, et al. Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: the Preoperative Palbociclib (POP) randomized trial. Cancer Res. 2016;76:CT041.
Malorni L, Piazza S, Ciani Y, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016;7:68012-68022. Abstract
Yang C, Li Z, Bhatt T, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36:2255-2264. Abstract
Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34:2961-2968. Abstract

CPD

CDK4/6 Inhibitors in Practice: Expert Insights and Perspectives

Authors: Martine Piccart, MD, PhD; Fabrice Andre, MD, PhD; Giuseppe Curigliano, MD, PhD; Angelo DiLeo, MD, PhD; Luca Gianni, MD; Peter Schmid, FRCP, MD, PhD
CPD Released: 9/27/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/27/2018, 11:59 PM EST

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor-positive advanced breast cancer.

The goal of this activity is to improve physician knowledge regarding treatment options for patients with hormone receptor-positive, human epidermal growth factor receptor (HER) 2-negative, metastatic breast cancer (MBC).

Upon completion of this activity, participants will have increased knowledge regarding the:

Clinical and pharmacological differences between cyclin-dependent kinase (CDK) 4/6 inhibitors
Mechanisms of resistance associated with CDK4/6 inhibitors
How CDK4/6 inhibitors work in different patient populations
Current evidence on the use of CDK4/6 inhibitors in clinical practice

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Martine Piccart, MD, PhD

Jules Bordet Institute, Université Libre de Bruxelles; Chair, Breast International Group (BIG AISBL), Brussels, Belgium

Disclosures

Disclosure: Martine Piccart, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abraxis Oncology; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Roche
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche; Sanofi

Fabrice André, MD, PhD

Professor of Medicine, Department of Medical Oncology, Université Paris Sud; Chairman, INSERM Unit U981, Institut Gustave Roussy, Villejuif, France

Disclosures

Disclosure: Fabrice André, MD, PhD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc

Giuseppe Curigliano, MD, PhD

Professor, University of Milano; Head, European Institute of Oncology, Milan, Italy

Disclosures

Disclosure: Giuseppe Curigliano, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Roche

Angelo Di Leo, MD, PhD

Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

Disclosures

Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bayer HealthCare; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Co., Ltd; Genomic Health; Ipsen; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Pierre Fabre; Puma Biotechnology; Roche

Luca Gianni, MD

Director, Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy

Disclosures

Disclosure: Luca Gianni, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ADC Therapeutics; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Genomic Health; Merck Sharp & Dohme Corp.; Odonate Therapeutics; Oncolytics Biotech Inc.; Onkaido; Pfizer Inc.; Roche; Sandoz; Seattle Genetics, Inc.; Synaffix; Synthon BV; Tahio Pharmaceutical

Peter Schmid, MD, PhD

Professor, Centre for Experimental Cancer Medicine, St. Bartholomew Hospital; Chair of Cancer Medicine and Honorary Consultant in Medical Oncology Barts Cancer Institute, Queen Mary University London, London, United Kingdom

Disclosures

Disclosure: Peter Schmid, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eisai Co., Ltd; Pfizer Inc; Puma Biotechnology

Editor

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Content Reviewer

Amy H. Seung, PharmD, BCOP

Disclosures

Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

CDK4/6 Inhibitors in Practice: Expert Insights and Perspectives

Authors: Martine Piccart, MD, PhD; Fabrice Andre, MD, PhD; Giuseppe Curigliano, MD, PhD; Angelo DiLeo, MD, PhD; Luca Gianni, MD; Peter Schmid, FRCP, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 9/27/2017

Valid for credit through: 9/27/2018, 11:59 PM EST

processing....

None
中文

Contents of This CPD Activity

All sections of this activity are required for credit.

CDK4/6 Inhibitors in Practice: What Are the Differences?

Drs Piccart and Curigliano discuss the pharmacological and clinical differences between the 3 CDK4/6 inhibitors and the relevance of those differences in clinical practice.
Martine Piccart, MD, PhD; Giuseppe Curigliano, MD, PhD

CDK4/6 Inhibitors in Premenopausal Patients: What Is the Evidence?

Dr DiLeo discusses the use of CDK4/6 inhibitors in premenopausal patients.
Angelo DiLeo, MD, PhD

Impact of CDK4/6 Inhibitors on the Treatment Sequence: What Is the Evidence?

Dr Gianni discusses the topic of sequencing approaches with CDK4/6 inhibitors.
Luca Gianni, MD

Selecting the Right Endocrine Partner for CDK4/6 Inhibitors

Dr Schmid discusses the current data regarding endocrine therapy used in combination with CDK4/6 inhibitors.
Peter Schmid, FRCP, MD, PhD

Resistance to CDK4/6 Inhibitors: What Do We Know?

Dr Andre discusses the mechanisms of resistance associated with CDK4/6 inhibitors.
Fabrice Andre, MD, PhD

Educational Impact Challenge

Assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 8

CPD Information Download Slides

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Martine Piccart, MD, PhD

Fabrice André, MD, PhD

Giuseppe Curigliano, MD, PhD

Angelo Di Leo, MD, PhD

Luca Gianni, MD

Peter Schmid, MD, PhD

Editor

Deborah Middleton, MS

Content Reviewer

Amy H. Seung, PharmD, BCOP

CPD

CDK4/6 Inhibitors in Practice: Expert Insights and Perspectives

Target Audience and Goal Statement

Disclosures

Faculty

Martine Piccart, MD, PhD

Fabrice André, MD, PhD

Giuseppe Curigliano, MD, PhD

Angelo Di Leo, MD, PhD

Luca Gianni, MD

Peter Schmid, MD, PhD

Editor

Deborah Middleton, MS

Content Reviewer

Amy H. Seung, PharmD, BCOP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

CDK4/6 Inhibitors in Practice: Expert Insights and Perspectives

Contents of This CPD Activity

CDK4/6 Inhibitors in Practice: What Are the Differences?

CDK4/6 Inhibitors in Premenopausal Patients: What Is the Evidence?

Impact of CDK4/6 Inhibitors on the Treatment Sequence: What Is the Evidence?

Selecting the Right Endocrine Partner for CDK4/6 Inhibitors

Resistance to CDK4/6 Inhibitors: What Do We Know?

Educational Impact Challenge